2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Yoda Pharmaceuticals Inc.

Company Presentations

Friday, July 24 Company Presentations 6–Taiwan BIO Award Winners

Yoda Pharmaceuticals Inc.

Company Info

Name /Yoda Pharmaceuticals Inc.

Address /3F., No. 35, Ln. 60, Wenhu St., Neihu Dist., Taipei City 114, Taiwan (R.O.C.)

Website /

Presenter

Name /Yufeng Jane Tseng

Title /Founder and Scientific Advisor

Email /janetseng@yodapharma.com

Telephone /(Work) (886)-2-33664888#403

Fax /

Mobile /

Company Type

Pharmaceutical

About the Company

Yoda Pharmaceuticals Inc. is an innovative drug development company founded in 2019 in Taiwan. Partnering with international experts, Yoda utilizes state-of-the-art AI technology and big data to develop novel compounds in new drugs for unmet medical needs in neuropsychological diseases and neurological diseases.  Yoda is committed to bring innovations and transform lives of patients – may the force be with all of us.

Brief Description of main products or services

RS-D7 is a novel NCE, with positive clinical data in treating schizophrenia and multiple systems atrophy. RS-D7 was jointly developed by professors and psychiatrists from NTU, NTU Hospital, NHRI, and NCTU in Taiwan, and licensed exclusively to Yoda Pharmaceuticals Inc. in 2019. Yoda is seeking investment to complete IND-enabling studies, IND filing, and clinical trials to advance the development and approval of RS-D7.

As an efficacious NCE to treat negative and cognitive symptoms of schizophrenia, RS-D7 differs from antipsychotics approved to date, which focus solely on treatment of positive and mood-related symptoms.  Clinical results from human studies indicate RS-D7 effectively improve patients’ verbal and visual memory and could potentially be used long-term, either alone or in combination with other CNS drugs.

In addition, RS-D7’s proof-of-concept clinical trial resulted in positive therapeutic effects on alleviation of ataxia-related motor deficits in mice, pointing to potential of it becoming the first-in-class drug to treat multiple systems astrophy (MSA). MSA with cerebellar ataxia is a progressive brain disorder affecting movement and balance and disrupts the autonomic nervous system.  Treatment of MSA and ataxia is an unmet medical need as existing agents have shown no promising effect in relieving symptoms of ataxia and uncoordinated movements.

Contact Person

Name /Da-Zhong Luo

Email /dzluo@yodapharma.com

Phone /02-33663957